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ABSTRACT
Rutin and quercetin, a flavone glycoside and its aglycone, are the flavonoids most widely and abundantly present in herbs and plant
foods. The aim of this study was to characterize and compare the bioavailability and metabolic pharmacokinetics of rutin and quercetin
in rats. Quercetin was administered intravenously (33 µmol/kg) and orally (165 µmol/kg), while rutin was administered only orally
(328 µmol/kg) to rats. Blood samples were withdrawn via cardiopuncture at specific time points. An HPLC method was used to
determine the concentrations of quercetin before and after hydrolysis using β-glucuronidase and sulfatase, respectively. The pharmacokinetic parameters were calculated using noncompartment model of WINNONLIN. The results showed that after intravenous administration of quercetin, 93.8% of the dose was circulating as its sulfates and glucuronides. After oral administration of quercetin, the glucuronides and sulfates of quercetin were exclusively present in the bloodstream, whereas the parent form of quercetin was not detected.
The oral absorption rate of quercetin was 53% compared to intravenous administration after dose correction. When rutin was orally
administered, sulfates and glucuronides of quercetin were exclusively present in the bloodstream, whereas rutin and quercetin were not
detected. Quercetin showed higher oral absorption rate than rutin. In conclusion, quercetin sulfates and quercetin glucuronides
represent the major metabolites either rutin or quercetin was administered to rats.
Key words: rutin, quercetin, conjugated metabolites, sulfates, glucuronides, pharmacokinetics

INTRODUCTION
Flavonoids are polyphenolic compounds containing a
unique C6-C3-C6 structure (diphenyl propane structure).
More than 4,000 varieties of flavonoids have been found in
herbs, vegetables, fruits and beverages (1) . Recently,
flavonoids have attracted increasing interest because of
their various beneficial biological activities to human
health(2) although some epidemiological studies reported a
negative correlation between flavonoid intake and the
occurrence of cardiovascular diseases and possibly
cancer(3,4,5).
Rutin and quercetin (structures shown in Figure 1), a
flavone glycoside and its aglycone, are the flavonoids most
widely and abundantly present in herbs and plant foods.
Quercetin has been reported to exert numerous pharmacological activities, such as free radical scavenging(6), TNFalpha inhibition(7), and anticarcinogenic effects(8,9). In
addition, quercetin markedly enhanced the absorption of
digoxin(10), but profoundly decreased the oral bioavailability of cyclosporine(11). Quercetin is mainly present in nature
as its glycosides in which one or more sugar groups are
bound to phenolic groups by glycosidic linkage. Rutin, a
very common quercetin glycoside, was recognized to
decrease the permeability of capillaries since 1946(12). It
* Author for correspondence. Tel: +886-4-22053366 ext. 1905;
Fax: +886-4-22031028; E-mail: pdlee@mail.cmu.edu.tw

has been reported to scavenge free radical, to lower hepatic
and blood cholesterol levels, and showed antiplatelet
activity(13,14).
In recent years, the biological fates of flavonoid glycosides are gradually understood that they are generally
hydrolyzed by intestinal and/or bacterial enzymes to corresponding aglycones which are absorbable by the gut(15).
Rutin was found being hydrolyzed to quercetin in the
intestine, then absorbed as quercetin and presented as conjugated metabolites of quercetin in the circulation (16) .
Many studies on the biological fates of quercetin and rutin
were reported, including metabolism of quercetin(17,18) and
pharmacokinetics of quercetin and rutin(19,20). However,
detailed information concerning the individual pharmacokinetics of quercetin glucuronides and quercetin sulfates still
remained limited. Therefore, in this study we attempted to
compare the bioactivities and metabolic pharmacokinetics
of oral quercetin with rutin in rats.

MATERIALS AND METHODS
I. Reagents and Chemicals
Rutin hydrate (purity 95%), quercetin dihydrate (purity
95%), glycofurol, acetic acid, β-glucuronidase (type B-1
from bovine liver) and sulfatase (type H-1 from Helix
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Figure 1. Chemical structures of quercetin and rutin.

pomatia) were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Acetonitrile, ethyl acetate and methyl
alcohol obtained from Mallinckrodt Baker, Inc. were of LC
grade (Phillipsburg, USA). Polyethylenglycol 400,
potassium dihydrogen phosphate were products of Merck
(Darmstadt, Germany). L (+)-Ascorbic acid was purchased
from RdH Laborchemikalien GmbH & Co. KG (Seelze,
Germany). 6,7-Dimethoxycoumarin (98%) was purchased
from Aldrich Chemical Co. (St. Louis, MO, USA). Sodium
acetate was obtained from Kohusan Chemical Works, Ltd.
(Kyoto, Japan). Milli-Q plus water (Millipore, Bedford,
USA) was used for all preparations.
II. Instrumentation and HPLC Conditions
HPLC system was equipped with a Shimadzu SIL10AD VP automatic sample injector, a Shimadzu SPD-10A
VP Detector and two Shimadzu LC-10AT VP pumps.
Reversed-phase separation was carried out using a RP-18
column (Cosmosil, 150 × 4.0 mm, 5 µm) equipped with a
prefilter. The mobile phase consisted of acetonitrile and
0.01% phosphoric acid (24:76) and the flow rate was 1.0
mL/min. The detection wavelength was set at 370 nm.
III. Drug Administration and Blood Collection
Male Sprague-Dawley rats weighing 300-380 g were
fasted for 12 hr before drug administration and continued
for another 3 hr. Water was supplied ad libitum. The
animal study adhered to “The Guidebook for the Care and
Use of Laboratory Animals (2002)” (published by The
Chinese Society for the Laboratory Animal Science,
Taiwan, ROC).
For intravenous administration (iv), quercetin was
dissolved in PEG 400 and filtered through a 0.22 µm

membrane. The iv bolus were given to 6 rats via the tail
vein at a dose of 33 µmol/kg. Blood samples (0.8 mL) were
withdrawn via cardiopuncture prior to dosing and at 5, 10,
15, 30, 60, 90, 120, 240, 360, 480 and 720 min post-dosing.
Water was supplied at 2-hr intervals via gastric gavage
during the experiment.
For oral administration (po), quercetin was dissolved
in PEG 400 and rutin was dissolved in glycofurol.
Quercetin and rutin were given at 165 µmol/kg and 328
µmol/kg, respectively, via gastric gavage. Blood samples
were withdrawn via cardiac puncture at 5, 15, 30, 60, 120,
240, 360, 480, 1440, 2160 and 2880 min post dosing of
quercetin, and at 5, 15, 30, 60, 120, 240, 420, 600, 1440,
2040, 2880, 3480, 4440 and 4920 min post dosing of rutin.
All blood samples were centrifuged at 9860×g for 15 min
and the serum obtained were stored at -30˚C until analysis.
IV. Determination of Quercetin Conjugated Metabolites in
Serum
The concentrations of quercetin glucuronides and
quercetin sulfates in serum were determined after β-glucuronidase and sulfatase treatments, respectively. For enzymolysis, 200 µL of serum sample was mixed with 100 µL of
β-glucuronidase (500 units/mL in pH 5 acetate buffer) or
sulfatase (1000 units/mL in pH 5 acetate buffer), 50 µL of
ascorbic acid (200 mg/mL) and incubated at 37˚C for 2 hr
and 1 hr, respectively, under anaerobic condition by sucking
air with syringe, and protected from light by wrapping with
aluminum foil. After hydrolysis, the serum was acidified
with 20 µL of 0.1 N HCl and partitioned with 350 µL of
ethyl acetate (containing 2.0 µg /mL of 6,7-dimethoxycoumarin as the internal standard). The ethyl acetate layer
was evaporated under N2 to dryness and reconstituted with
an appropriate volume of methanol prior to HPLC analysis.
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V. Validation of Assay Method for Serum
The system suitability was evaluated through intra-day
and inter-day analysis of precision and accuracy. The
accuracy of this method was further assessed with recovery
studies by spiking methanolic quercetin standard solution
into blank serum and water in triplicates to afford 0.2, 12.5
and 100.0 µg/mL, respectively. Afterwards, the concentrations obtained in blank serum to the corresponding ones in
water were compared. The LLOQ (lower limit of quantitation) represents the lowest concentration of analysis in a
sample that can be determined with acceptable precision
and accuracy, whereas LOD (limit of detection) represents
the lowest concentration of analysis in a sample that can be
detected with signal/noise greater than 3.

calculated using trapezoidal rule to the last point. The other
pharmacokinetic parameters were calculated using the
following relationships:
Oral absorption rate of Q = AUC0-t (Q conjugates) of Q po
/ AUC0-t (Q free form +Q conjugates) of Q iv × 5
(Q: quercetin)
VII. Statistical Analysis
The paired Student’s t-test was used to compare the
difference of pharmacokinetic parameters between sulfates
and glucuronides of quercetin, and p < 0.05 was considered
significant.

RESULTS
VI. Data Analysis
The peak serum concentration (Cmax) and the time to
peak concentration (Tmax) were obtained from experimental
observation. The pharmacokinetic parameters were
analyzed by noncompartmental method with the aid of the
program WINNONLIN (version 1.1 SCI software,
Statistical Consulting, Inc., Apex, NC, USA). The area
under the serum concentration-time curve (AUC0-t) was
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Figure 2. Chromatograms of (A) blank serum; (B) serum spiked with
quercetin (12.5 µg/mL) and internal standard; and (C) a serum sample
hydrolyzed with sulfatase (quercetin: 8.3 µg/mL); 1: internal standard
(6,7-dimethoxycoumarin); 2: quercetin.

Typical chromatograms of blank serum and quercetin
in serum are shown in Figure 2. Good linear relationship
was obtained for quercetin within the concentration range
of 0.2-100.0 µg/mL (Y = 0.57 X – 0.02, r = 0.999). The
intra-day and inter-day precision and accuracy analysis of
quercetin in serum indicated that the coefficients of variations and the relative errors were below 10.1 and 6.7%,
respectively, as shown in Table 1. The recoveries of
quercetin from serum were 90.9 ± 6.1, 89.3 ± 2.2 and 105.3
± 1.4% for the concentrations of 0.2, 12.5 and 100.0 µg/mL,
respectively. The LLOQ was 0.2 µg/mL and LOD was
estimated as 0.05 µg/mL.
Mean serum concentration - time profiles of quercetin
and its conjugates after iv administration of quercetin are
shown in Figure 3. After iv bolus, no parent form was
detected after 60 min and the blood levels of quercetin
sulfates and quercetin glucuronides were much higher than
their parent form during the experiment. The half-life of
quercetin parent form was 21 min which was shorter than
those of quercetin sulfates (371 min) and quercetin glucuronides (561 min). The AUC 0-60 of quercetin parent
form and its conjugates listed in Table 2 indicated that the
conjugated metabolites accounted for 93.8% of the total
quercetin including the parent form and its conjugates in
the circulation. The mean AUC0-t of quercetin sulfates was

Table 1. Intra-day and inter-day analytical precision and accuracy of quercetin in serum (n = 3)
Intra-day
Conc.
Precision
Accuracy
Precision
(µg/mL)
Mean ± S.D. (C.V.%)
(%)
Mean ± S.D. (C.V.%)
100.0
106.7 ± 0.6 (0.6)
6.7
106.0 ± 0.3 (0.3)
50.0
52.6 ± 0.4 (0.8)
5.3
52.5 ± 0.0 (2.2)
25.0
25.8 ± 0.1 (0.2)
3.3
25.8 ± 0.2 (0.9)
12.5
12.6 ± 0.0 (0.3)
0.5
12.5 ± 0.1 (0.5)
6.3
6.1 ± 0.0 (0.3)
-2.6
6.1 ± 0.0 (0.6)
3.1
3.0 ± 0.0 (0.4)
-5.6
2.9 ± 0.0 (0.8)
1.6
1.5 ± 0.0 (0.7)
-3.1
1.5 ± 0. 0 (1.5)
0.8
0.8 ± 0.0 (1.2)
-3.9
0.8 ± 0.0 (1.8)
0.4
0.4 ± 0.0 (5.2)
-3.9
0.4 ± 0.0 (3.7)
0.2
0.2 ± 0.0 (1.6)
6.5
0.2 ± 0.0 (10.1)

Inter-day
Accuracy
(%)
6.0
5.0
3.2
0.2
-2.5
-6.2
-2.7
-4.3
0.8
4.5
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Table 2. Comparison of pharmacokinetic parameters of quercetin sulfates and glucuronides in serum after intravenous administration of 10
mg/kg (33 µmol/kg) quercetin to 6 rats
Quercetin
Free form
Sulfates
Glucuronides
Parameter
a
-1
114.1 ± 11.9
1606.8 ± 187.6
311.2 ± 63.8e
AUC0-60 (nmol•min•mL )
b
-1
AUC0-t (nmol•min•mL )
450.1 ± 65.3
6662.3 ± 923.6
1931.8 ± 524.0f
c
T1/2 (min)
20.7 ± 5.9
371.2 ± 17.2
560.7 ± 235.9
MRTd (min)
223.4 ± 50.4
473.4 ± 24.7
716.8 ± 335.1
Data expressed as means ± S.E.
a
Area under the serum concentration-time curve from time zero to 60 min.
b
Area under the serum concentration-time curve from time zero to the last point.
c
Half-life.
d
Mean residence time.
e
p < 0.001.
f
p < 0.01.

Concentration in serum (nmol/mL)

Concentration in serum (nmol/mL)

50
Sulfates
Glucuronides
Free form

40

30

20

10

0
5 30 60

120

240

360

480

720

Time (min)

Figure 3. Mean (± S.E.) serum concentration - time profiles of
quercetin and its conjugated metabolites after intravenous administration of quercetin (33 µmol/kg) to 6 rats.

significantly higher than that of quercetin glucuronides by
245% (p < 0.01). The mean residence times of quercetin
sulfates and glucuronides were longer than quercetin.
After oral dosing of quercetin, no parent form of
quercetin was detected in serum. The serum profiles of
quercetin conjugates are shown in Figure 4. The concentrations of quercetin sulfates were markedly higher than
quercetin glucuronides at each time point. The pharmacokinetic parameters of quercetin conjugates are listed in
Table 3. The mean Cmax of quercetin sulfates was significantly higher than that of quercetin glucuronides by 129%
(p < 0.01). Similarly, the mean AUC 0-t of quercetin
sulfates was significantly higher than that of glucuronides
by 161% (p < 0.001). Because the oral dose of quercetin
was 5 times of intravenous dose in this study, after dose
correction, the oral absorption rate of quercetin was about
53% based on comparing the AUC0-t of quercetin conjugates after oral dosing with that of the total quercetin
including quercetin and its conjugates after iv bolus.
After oral dosing of rutin, no rutin or quercetin was
detected. The serum profiles of quercetin conjugates are
shown in Figure 5. The serum level of quercetin sulfates
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Figure 4. Mean (± S.E.) serum concentration - time profiles of conjugated metabolites of quercetin after oral administration of quercetin
(165 µmol/kg) to 6 rats.

Table 3. Comparison of pharmacokinetic parameters of quercetin
sulfates and glucuronides in serum after oral administration of 50
mg/kg (165 µmol/kg) quercetin to 6 rats
Quercetin conjugates
Sulfates
Glucuronides
Parameter
Cmaxa (nmol•mL-1)
27.3 ± 8.1
11.9 ± 1.3
17756.4 ± 2879.1 6803.8 ± 1000.3d
AUC0-tb (nmol•min•mL-1)
MRTc (min)
1265.1 ± 71.6
1063.7 ± 15.8e
Data expressed as means ± S.E.
a
Peak serum concentration.
b
Area under the serum concentration - time curve from time zero to
the last point.
c
Mean residence time.
d
p < 0.01.
e
p < 0.05.

was markedly higher than that of quercetin glucuronides at
each time point. The pharmacokinetic parameters of
quercetin conjugates are listed in Table 4. The mean Cmax
of quercetin sulfates was significantly higher than that of
quercetin glucuronides by 126% (p < 0.01). The mean
AUC0-t of quercetin sulfates was significantly higher than
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Table 4. Comparison of pharmacokinetic parameters of quercetin
sulfates and glucuronides in serum after oral administration of 200
mg/kg (328 µmol/kg) rutin to 6 rats
Quercetin conjugates
Sulfates
Glucuronides
Parameter
5.2 ± 1.2
2.3 ± 0.7d
Cmaxa (nmol•mL-1)
b
-1
AUC0-t (nmol•min•mL )
3533.0 ± 750.4
161.0 ± 63.1d
c
MRT (min)
1644.5 ± 148.2
272.9 ± 84.1d
Data expressed as means ± S.E.
a
Peak serum concentration.
b
Area under the serum concentration-time curve from time zero to the
last point.
c
Mean residence time.
d
p < 0.01.
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Figure 5. Mean (± S.E.) serum concentration - time profiles of conjugated metabolites of quercetin after oral administration of rutin (328
µmol/kg) to 6 rats.

that of quercetin glucuronides by 2094% (p < 0.01) and the
mean residence time of quercetin sulfates was longer than
quercetin glucuronides.

DISCUSSION
The quercetin sulfates and quercetin glucuronides in
serum cannot be determined directly due to the lack of
authentic standard. Therefore, the concentrations of
quercetin in serum sample were determined before and after
respective treatment with β-glucuronidase or sulfatase in
order to calculate the concentrations of quercetin sulfates
and glucuronides. The conditions for enzymolysis were
optimized, including sufficient reaction time, protection
from light and addition of antioxidant. As a result, ascorbic
acid was added to the serum for antioxidation and the incubation was conducted anaerobically and protected from
light to prevent the potential decomposition of quercetin
liberated from its sulfates and glucuronides. Validation
indicated that the present assay methods were precise and
accurate, and thus applicable in pharmacokinetic studies of
quercetin and its conjugated metabolites.
The serum profiles of quercetin parent form and its
conjugated metabolites after iv bolus of quercetin indicated
that conjugation metabolism of quercetin occurred very
rapidly and extensively. In addition, the half-lives of
quercetin sulfates and glucuronides were longer than their
parent form by 2~3-fold, possibly due to their enterohepatic
circulation(21,22). Because rutin was not absorbed per se,
intravenous pharmacokinetics of rutin can not afford any
information about its bioavailability. Therefore, intravenous administration of rutin was not conducted.
When quercetin and rutin were administered orally, the
glucuronides and sulfates of quercetin appeared at the first
time point (5 min post dosing) and were exclusively circulating in the bloodstream, indicating very rapid absorption

of quercetin and simultaneous sulfation and glucuronidation
during absorption. Additional peaks of both quercetin conjugates were observed during the apparent elimination
phase in Figures 4 and 5, implying enterohepatic circulation
of these conjugated metabolites. The parent forms of
quercetin and rutin were not detected, indicating that the
absolute systemic bioavailabilities of quercetin and rutin
were essentially zero. Together with the finding of the null
absolute systemic bioavailability of baicalein (23), these
results indicated that extensive conjugation metabolism of
polyphenols occurred during the first pass through gut and
liver. These facts are in good agreement with previous
polyphenol studies(24,25), which stated that glucuronidation/sulfation was central to the flavonoid metabolism and
absorption. The absorption rate of quercetin (53%) was
higher than that of baicalein (40%) in our previous
study(23). This could be accounted for by the fact that the
lipophilicity of quercetin was greater than baicalein from
the observation of its longer retention time on the reversed
phase HPLC chromatogram (data not shown).
After dose correction, much lower Cmax and AUC0-t of
quercetin sulfates and quercetin glucuronides were shown
for oral rutin than quercetin, indicating that the rate and
extent of quercetin absorption was much higher than its
glycoside - rutin. One of the reasons for poor absorption of
rutin is that it is too hydrophilic to diffuse through cell
plasma membrane and it was absorbable only after being
hydrolyzed into quercetin which is absorbable. Therefore,
the hydrolysis of rutin was indispensable for its absorption
and this can account for the null bioavailability of rutin.
Recently, two quercetin metabolites, quercetin 3-O-βD-glucuronide and quercetin 3’-O-sulfate in human plasma
were reported after consumption of onions(26). Another
study also identified glucuronides and sulfates of quercetin
from plasma after oral dosing of quercetin 4’-O-β-glucoside
to rats(27). In this study, oral administration of rutin or
quercetin resulted in predominant presence of quercetin
sulfates in the circulation. Therefore, the conjugated
metabolites of quercetin, in particular quercetin sulfates,
might be responsible for the in vivo effects of quercetin and
rutin. Nowadays, there is proliferation of in vitro studies of
polyphenols. Nonetheless, the bioactivies of parent form of
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quercetin and rutin investigated in vitro could not explain
the in vivo effects of oral quercetin and rutin. In addition,
recent study on quercetin 3-glucuronide (Q3GA) reported
that Q3GA was more effective than quercetin aglycone in
the inhibition of H2O2-induced intracellular ROS production in mouse fibroblast cultured cells, although little
Q3GA diffused into the cytoplasm or cell nucleus compartment(28). A recent study on morin and its sulfates/glucuronides also demonstrated that the conjugated metabolites
of morin were 1000-fold more effective than morin
aglycone in anti-inflammation activity(29).
In conclusion, quercetin and rutin were transformed
into sulfates and glucuronides of quercetin in vivo.
Therefore, various bioactivities of quercetin sulfates and
glucuronides are worthy for further investigations.
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